EMA to review label extension for Eisai's Zonegran as epilepsy monotherapy
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMA) has accepted for review Eisai's application to extend the use of the antiepileptic agent, Zonegran (zonisamide), as a monotherapy.